

CSD/BSE&NSE/2025-26

April 1, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

**Sub: Cautionary email received from the NSE regarding delay in intimation to Stock exchanges**

**Ref:**

- 1) Email dated April 1, 2025, received from NSE**
- 2) Our disclosure dated July 12, 2024, to the stock exchanges.**

We would like to inform that the Company has received cautionary email from the National Stock Exchange of India Limited (“NSE”) regarding delay in intimating to the Stock exchanges with respect to the appointment of Statutory Auditors of the Company on July 12, 2024.

The information as required in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), pertaining to the said cautionary email, is annexed as Annexure – 1.

Further, the email communication received from NSE is annexed as Annexure – 2.

In this connection, please note that we will ensure compliance with the disclosure requirements as required under Regulation 30 of the SEBI Listing Regulations.

This is for your information and record.

Thanking you.

Yours faithfully,  
**For Suven Pharmaceuticals Limited**

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer  
and Head-Legal*

Encl: as above

## **Suven Pharmaceuticals Limited**

**Registered Office:** # 215 Atrium, C Wing, 8th Floor,  
819-821, Andheri Kurla Road, Chakala, Andheri East,  
Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers,  
Plot No.1, Hyderabad Knowledge City, TSIC,  
Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236

**Annexure – 1**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Details</b>
1	Name of the authority	National Stock Exchange of India Limited (“NSE”)
2	Nature and details of the action(s) taken, or order(s) passed by the Authority	The Company has received a cautionary email on April 1, 2025 from NSE with respect to the announcement submitted by the Company on July 12, 2024 regarding the appointment of Statutory Auditors of the Company.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	April 1, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in intimating to the stock exchanges with respect to the appointment of Statutory Auditors of the Company, on July 12, 2024, i.e., intimation was not submitted within the prescribed timelines of 30 minutes of conclusion of the Board Meeting as per Regulation 30 of the SEBI Listing Regulations.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the financial, operation or other activities of the Company on account of the above.

## Suven Pharmaceuticals Limited

**Registered Office:** # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236



---

**SUVENPHAR - Cautionary Email**

---

**From** neaps@nse.co.in <neaps@nse.co.in>

**Date** Tue 2025-04-01 17:39

**To** Kundan Kumar Jha

**CAUTION:** This email originated from outside of Suven Pharmaceuticals Limited. Do not click links or open attachments unless you recognize the sender and know the content is safe. Please also read the sender email address carefully.

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on July 12, 2024 regarding the appointment of Statutory Auditors of the Company.

As per Regulation 30 read with sub-para 7 of Para A Part A of Schedule III of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in case of appointment of directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer shall be disclosed to the Stock Exchanges by the listed entities within 30 minutes of conclusion of the Board Meeting.

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of 30 minutes of conclusion of the Board Meeting as per sub-para 7 of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at [takeover@nse.co.in](mailto:takeover@nse.co.in).

**Confidentiality Notice:**

This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please delete the message and any attachments from your Inbox.